Acute Coronary Syndrome - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 128 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acute Coronary Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acute Coronary Syndrome - Pipeline Review, H2 2014', provides an overview of the Acute Coronary Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Coronary Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Coronary Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Coronary Syndrome - Overview 10
Pipeline Products for Acute Coronary Syndrome - Comparative Analysis 11
Acute Coronary Syndrome - Therapeutics under Development by Companies 12
Acute Coronary Syndrome - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Acute Coronary Syndrome - Products under Development by Companies 18
Acute Coronary Syndrome - Companies Involved in Therapeutics Development 20
AstraZeneca PLC 20
GlaxoSmithKline plc 21
MedImmune, LLC 22
The Medicines Company 23
Pfizer Inc. 24
Bayer AG 25
Ligand Pharmaceuticals, Inc. 26
Arena Pharmaceuticals, Inc. 27
CSL Limited 28
XOMA Corporation 29
Auspex Pharmaceuticals, Inc. 30
Regado Biosciences, Inc. 31
Vitae Pharmaceuticals, Inc. 32
Athera Biotechnologies AB 33
Lacer, S.A. 34
Lee's Pharmaceutical Holdings Limited 35
Esperion Therapeutics, Inc. 36
Artery Therapeutics, Inc. 37
advanceCor GmbH 38
Acute Coronary Syndrome - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
rivaroxaban - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
cangrelor - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BAY-818781 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
clopidogrel bisulfate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CSL-112 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
gevokizumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MTP-131 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ZK-001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PR-15 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
temanogrel hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MDCO-216 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
losmapimod - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MEDI-6012 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PF-06282999 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SD-970 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tirofiban hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
PC-mAb - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
LA-8045 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
COR-3 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
COR-2 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
AEM-28 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
bivalirudin - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
PMC-6 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
4-WF - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
VTP-38443 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Artpep-2 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
AEM-28 Analogs - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Aptamers for Cardiovascular Diseases - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Acute Coronary Syndrome - Recent Pipeline Updates 92
Acute Coronary Syndrome - Dormant Projects 115
Acute Coronary Syndrome - Discontinued Products 116
Acute Coronary Syndrome - Product Development Milestones 117
Featured News & Press Releases 117
Jul 23, 2014: Daiichi Sankyo and Eli Lilly and Company: Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel 117
Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 118
May 13, 2014: GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome 118
May 08, 2014: FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients 119
Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome 120
Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 121
Sep 03, 2013: Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published 122
Jul 24, 2013: Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine 123
Jun 28, 2013: FDA Issues Complete Response Letter for XARELTO to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome 123
Jun 24, 2013: Bayer To Present New Data On Clinical Benefit Of Xarelto At ISTH 2013 124
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 128
Disclaimer 128

List of Tables
Number of Products under Development for Acute Coronary Syndrome, H2 2014 10
Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Development by Companies, H2 2014 (Contd..1) 19
Acute Coronary Syndrome - Pipeline by AstraZeneca PLC, H2 2014 20
Acute Coronary Syndrome - Pipeline by GlaxoSmithKline plc, H2 2014 21
Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H2 2014 22
Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2014 23
Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2014 24
Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2014 25
Acute Coronary Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 26
Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2014 27
Acute Coronary Syndrome - Pipeline by CSL Limited, H2 2014 28
Acute Coronary Syndrome - Pipeline by XOMA Corporation, H2 2014 29
Acute Coronary Syndrome - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 30
Acute Coronary Syndrome - Pipeline by Regado Biosciences, Inc., H2 2014 31
Acute Coronary Syndrome - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 32
Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2014 33
Acute Coronary Syndrome - Pipeline by Lacer, S.A., H2 2014 34
Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 35
Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2014 36
Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H2 2014 37
Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2014 38
Assessment by Monotherapy Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 42
Number of Products by Stage and Mechanism of Action, H2 2014 45
Number of Products by Stage and Route of Administration, H2 2014 47
Number of Products by Stage and Molecule Type, H2 2014 49
Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 92
Acute Coronary Syndrome - Dormant Projects, H2 2014 115
Acute Coronary Syndrome - Discontinued Products, H2 2014 116